| NCT ID | NCT06526533 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Australian and New Zealand Intensive Care Research Centre |
| Condition | Extracorporeal Membrane Oxygenation Complication |
| Study Type | INTERVENTIONAL |
| Enrollment | 600 participants |
| Start Date | 2026-03-23 |
| Primary Completion | 2028-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 600 participants in total. It began in 2026-03-23 with a primary completion date of 2028-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this platform trial is to determine the efficacy, safety and cost-effectiveness of various interventions in patients with acute cardiorespiratory failure requiring extracorporeal membrane oxygenation (ECMO) The main question the platform trial aims to address is to determine the effect of a range of interventions on survival, organ support and resource utilisation to day 28 for hospitalised patients receiving ECMO. Researchers will compare various interventions within multiple platform trial domains to see if the interventions have effects on survival, organ support and resource utilisation for the patient cohort. Participants will be enrolled in accordance with the platform trial's domain structure to answer the research questions.
Eligibility Criteria
PLATFORM INCLUSION CRITERIA: * Patients receiving ECMO * Patients enrolled in the EXCEL Registry - NCT03793257 PLATFORM EXCLUSION CRITERIA: * Treating clinician regards death as imminent and inevitable * Treating clinician determines it is not in the patient's best interests RBC TRANSFUSION DOMAIN INCLUSION CRITERIA: • Aged 18 years or older RBC TRANSFUSION DOMAIN EXCLUSION CRITERIA: * Contraindication to RBC transfusion (including known patient preference) * Limitations of care put in place either through patient wishes or the treating medical teams. * Participant has already received ECMO \>12 hours. The start of ECMO is defined as the time of initiation of extracorporeal blood flow unless ECMO was initiated during a surgical intervention in which case the start of ECMO is defined as the arrival time into the initial ICU (post-surgery) * The treating physician anticipates that ECMO treatment will cease before the end of tomorrow * The treating physician deems the study is not in the patient's best interest * The treating physician has concern regarding patient ability to tolerate restrictive or liberal transfusion trigger thresholds * Actively listed for a solid organ transplant and has not yet received one * Suspected or confirmed to be pregnant * Previous ECMO treatment during the same hospital admission
Contact & Investigator
Carol Hodgson, PhD FACP FAHMS
STUDY CHAIR
Monash University
Frequently Asked Questions
Who can join the NCT06526533 clinical trial?
This trial is open to participants of all sexes, studying Extracorporeal Membrane Oxygenation Complication. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06526533 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 600 participants.
Is NCT06526533 currently recruiting?
Yes, NCT06526533 is actively recruiting participants. Contact the research team at curtis.hopkins@monash.edu for enrollment information.
Where is the NCT06526533 trial being conducted?
This trial is being conducted at Camperdown, Australia, Sydney, Australia, Melbourne, Australia.
Who is sponsoring the NCT06526533 clinical trial?
NCT06526533 is sponsored by Australian and New Zealand Intensive Care Research Centre. The principal investigator is Carol Hodgson, PhD FACP FAHMS at Monash University. The trial plans to enroll 600 participants.